Streetbeat News

Price Targets

ACXP

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Acurx Pharmaceuticals (NASDAQ:ACXP) but lowers the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:15 am

KNTE

HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Kinnate Biopharma (NASDAQ:KNTE) and maintained a $24 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 11:15 am

ZYME

HC Wainwright & Co. analyst Robert Burns has reiterated a neutral rating on Zymeworks (NASDAQ:ZYME) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 11:14 am

HALO

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Halozyme Therapeutics (NASDAQ:HALO) but lowers the price target from $61 to $60.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:13 am

ORIC

HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on ORIC Pharmaceuticals but lowers the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:10 am

VIRX

HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Viracta Therapeutics (NASDAQ:VIRX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:08 am

NAPA

B of A Securities analyst Peter Galbo maintains a Buy rating on Duckhorn Portfolio (NYSE:NAPA) but lowers the price target from $20 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:07 am

PSTV

HC Wainwright & Co. analyst Sean Lee has reiterated a 'Buy' rating on Plus Therapeutics (NASDAQ:PSTV) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 11:05 am

SUI

JMP Securities analyst Aaron Hecht maintains an 'Outperform' rating on Sun Communities (NYSE:SUI) but has lowered the price target from $160 to $150.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:05 am

NVDA

UBS analyst Timothy Arcuri maintains a Buy rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $475 to $540.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 11:03 am